Neoplasm News and Research

RSS
Neoplasm is an abnormal mass of tissue as a result of neoplasia.
Common drug for autoimmune disease may increase risk of myeloid neoplasms

Common drug for autoimmune disease may increase risk of myeloid neoplasms

Study evaluates long-term safety of infants after maternal MRI exposure

Study evaluates long-term safety of infants after maternal MRI exposure

Study finds racial, ethnic disparities in utilization rate and health outcomes after TKR surgery

Study finds racial, ethnic disparities in utilization rate and health outcomes after TKR surgery

Researchers find oldest evidence of cancer in 1.7 million-year-old fossil

Researchers find oldest evidence of cancer in 1.7 million-year-old fossil

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

CNIO study shows proinflammatory molecule IL-17A can be key factor in development of NASH and HCC

New method helps quantify HSATII RNA in blood serum of pancreatic cancer patients

New method helps quantify HSATII RNA in blood serum of pancreatic cancer patients

International panel reclassifies a type of thyroid tumor to reduce cancer overdiagnosis

International panel reclassifies a type of thyroid tumor to reduce cancer overdiagnosis

Multimodal MRI recommended to prevent brain mass misdiagnosis

Multimodal MRI recommended to prevent brain mass misdiagnosis

Common mortality causes prevail in epilepsy patients

Common mortality causes prevail in epilepsy patients

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

Daiichi Sankyo, Plexxikon’s Phase 1 trial shows PLX3397 induced prolonged tumor regression in TGCT patients

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

Positive results from pacritinib Phase 3 trial for treatment of myelofibrosis presented at ASCO 2015

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

JAK2 inhibitor ruxolitinib shows promise in treating CMML patients

No evidence for cancer risk with growth hormone therapy

No evidence for cancer risk with growth hormone therapy

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

VolitionRx's NuQ blood-based diagnostic platform demonstrates promising results in clinical study

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Gastroenteropancreatic neuroendocrine tumors: an interview with Dr. Alexandria Phan

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis

CTI completes recruitment in PERSIST-1 clinical trial of pacritinib for treatment of myelofibrosis